Skip to main content
Premium Trial:

Request an Annual Quote

Chris Ashton, David Evjen


Chris Ashton has become CEO of Etiologics in Oxford, UK. He joins the company from Orchid Bioscience, where he was CEO. Prior to that, he was commercial director of Inpharmatica and, previously, business development and marketing director at Oxford GlycoSciences.

At OGS, Ashton was responsible for initiating and negotiating partnerships with pharmaceutical and biotech companies. He also helped the company go public on the London Stock Exchange and raise $40 million.

Ashton also spent seven years at Applied Biosystems Europe. Ashton holds a BSc in biochemistry and a PhD in organic chemistry from the University of Manchester Institute of Science and Technology, and did postdoctoral research at the Massachusetts Institute of Technology. Etiologics provides novel mouse strains that can be used as disease models.

David Evjen has become CEO of Technologene, a startup company based in Lose Gatos, Calif. Evjen is the co-founder and former CEO of Med-Cor and Staff Outsourcing Solutions. He will be responsible for business development and focusing the company’s strategy, as well as guiding legal and public affairs functions. Technologene owns a patent for a process to produce industrial-grade proteins.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.